Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

Á Rodríguez-Lescure, J Gallego… - … Translational Oncology, 2024 - Springer
Arterial hypertension (AHT) is a common toxicity with bevacizumab (BVZ)-containing …
Once we could not correlate the AHT, with PFS to CT/BVZ, we evaluated several cut-offs of …

Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two …

P Lombardi, D Rossini, V Crespi, MM Germani… - Cancer Treatment …, 2022 - Elsevier
… Ten studies included patients treated with bevacizumab in the first line setting, whereas four
… the correlation between bevacizumab-induced HTN and survival outcomes in patients with …

… hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor …

H Osumi, E Shinozaki, A Ooki, T Wakatsuki… - Cancer …, 2021 - Wiley Online Library
bevacizumab (BEV) exposure in mCRC patients who were … In this study a strong correlation
was observed between the … especially in patients treated with BEV in first-line chemotherapy. …

The Effect of Bevacizumab-Related Hypertension on the Prognosis of Patients with Colorectal Cancer and Non-Small Cell Lung Cancer.

J Pan, L Zheng, B Liu, S You… - Indian Journal of …, 2022 - search.ebscohost.com
… and it is often used as the first-line therapy for metastatic colorectal cancer and locally
advanced, recurrent or … Therefore, the correlation between bevacizumab and the prognosis of …

Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis

D Sur, CI Coroama, A Audisio, R Fazio… - Journal of Personalized …, 2024 - mdpi.com
… Background: Arterial hypertension is regarded as a possible … that HTN is positively correlated
with CRC risk and can bring … analysed only the impact of bevacizumab-related HTN, whilst …

Basal VEGF-a and ACE plasma levels of metastatic colorectal cancer patients have prognostic value for first-line treatment with chemotherapy plus bevacizumab

MJ Ortiz-Morales, M Toledano-Fonseca… - Cancers, 2022 - mdpi.com
… -EGFR; no indication for bevacizumab due to uncontrolled arterial hypertension and/or …
correlation between plasma VEGF-A and outcomes in mCRC patients treated with bevacizumab

Relationship between safety and cumulative bevacizumab dose in patients with metastatic colorectal cancer who received long-term bevacizumab treatment

S Fukuda, Y Niisato, M Tsuji, S Fukuda… - Anticancer …, 2023 - ar.iiarjournals.org
… progression-free survival time with first-line chemotherapy, including bevacizumab, is 8-15 …
dose of bevacizumab was correlated with the risk of developing proteinuria and hypertension, …

Both new-onset and pre-existing hypertension indicate favorable clinical outcomes in patients treated with anti-vascular endothelial growth factor therapy

S Moriyama, M Hieda, M Kisanuki, S Kawano… - Circulation …, 2024 - jstage.jst.go.jp
patients with metastatic colorectal carcinoma that progressed during or after firstline therapy
with bevacizumab, … in glioblastoma: No correlation with clinical outcome. J Neurooncol 2010; …

Bevacizumab in combination with TAS‐102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: A retrospective study

H Fujii, N Matsuhashi, M Kitahora, T Takahashi… - The …, 2020 - academic.oup.com
correlation between Bmab and OS. The incidence of … combined treatment with Bmab
improves clinical outcomes, we … safety of treatment with or without bevacizumab in patients with …

Effect of bevacizumab in combination with standard oxaliplatin-based regimens in patients with metastatic colorectal cancer: a randomized clinical trial

A Avallone, MC Piccirillo, G Nasti, G Rosati… - JAMA Network …, 2021 - jamanetwork.com
… Assuming an ORR of 40% in the first line and 20% in the second line, an anticipated odds
… The number of BRAF-altered tumors was too small to allow correlation with outcomes. The …